Core Insights - Kailera has officially launched three global multi-center Phase III clinical trials for its core candidate drug KAI-9531, targeting obesity with type 2 diabetes and obesity without diabetes, marking a critical stage in clinical validation [4] - The trials aim to enroll over 4,700 participants, demonstrating the company's commitment to long-term safety and efficacy validation of the drug [4] - The studies are designed to progress simultaneously across multiple countries and regions, with completion expected between March and April 2028, potentially leading to regulatory submission and commercialization [6] Clinical Development - The Phase III trial for obesity with diabetes plans to enroll approximately 1,700 participants, while the two trials for obesity alone aim for around 1,200 and 1,800 participants respectively [4] - Kailera is accelerating the late-stage development of its obesity and metabolic disease product pipeline to secure a position in the competitive GLP-1 and novel metabolic drug market [6] Industry Context - GLP-1 receptor agonists are a new class of hypoglycemic drugs that enhance insulin secretion and suppress glucagon secretion in a glucose-dependent manner, also delaying gastric emptying and reducing appetite, thus aiding in blood sugar control and weight loss [14]